After state regulators rejected East Windsor’s argument that it’s carrying way too much of the burden of Connecticut’s solar energy industry, the town is preparing to appeal the approval of a highly ...

Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

The latest price target for Replimune Group (NASDAQ:REPL) was reported by BMO Capital on November 3, 2025. The analyst firm set a price target for $11.00 expecting REPL to rise to within 12 months (a ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...

Despite a sharp drop in the previous session following the FDA rejection of its skin cancer drug RP1, Replimune (NASDAQ:REPL) shares bounced back on Wednesday even as multiple Wall Street analysts ...

NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal ...

A self-hosting Python REPL with Gemini AI integration, featuring conversation context, tool use, and logging. $ gmake repl ╔══════════════════════════════════════╗ ║ 🌟 ...